Keytruda works by inhibiting the activity of the programmed cell death protein 1 (PD-1), which typically limits the activity of your immune system. Cancer cells often produce PD-1 to prevent your ...
Trodelvy plus Keytruda improved progression-free survival in PD-L1–positive, advanced TNBC, reducing disease progression or death risk by 35% compared to chemotherapy plus Keytruda. The phase 3 ASCENT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback